Dasatinib targets not only BCR-ABL but also cKIT, platelet-derived growth factor receptor (PDGFR), and SRC family kinases (SFKs), and it is currently mainly used for the treatment of CML patients positive for Philadelphia chromosome [65]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.